Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.61

-0.6%

Nov 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harold Engstrom who wrote (3694)	5/8/2001 11:44:05 AM
From: IRWIN JAMES FRANKEL	Read Replies (1) of 52153

BGEN - The quote I found most significant is: "Patients treated with Avonex® had 50% more new lesions in the brain than those treated with Rebif®. This result is also highly statistically significant with a p value less than 0.0001." Defining exacerbations is rather subjective, determined by interogating the patient. Lesions which they must be defining by MRI should be more reliable. With a P value UNDER .0001 it is stunning. Unless there is something screwy going on Rebif should get approved promptly. I can't believe that the significance of this news is in BGEN. VL indicates that 78% of revenue comes from Avonex. I would not want to hold BGEN and wait for AMEVIVE, good as it sounds. ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next